Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure and cardiovascular death among patients with chronic heart failure …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2)
reduce the risk of a first hospitalization for heart failure, possibly through glucose-…

Background Mineralocorticoid-receptor antagonists improve the prognosis for patients with
heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of …

Background— Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone
Antagonist (TOPCAT) patients with heart failure and preserved left ventricular ejection …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

Background Ferric carboxymaltose therapy reduces symptoms and improves quality of life
in patients who have heart failure with a reduced ejection fraction and iron deficiency. …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Aims While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit
patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the …

Importance Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance
decongestion and preserve renal function in patients with acute heart failure and renal …

Importance Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF).
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …